Four-Drug attack on deadly prostate cancer shows promise
NCT ID NCT04709276
Summary
This study is testing a combination of four drugs (nivolumab, ipilimumab, cabazitaxel, and carboplatin) in men with a rare, aggressive form of prostate cancer that has spread. The goal is to see if this intensive treatment can stop the cancer from growing for at least 6 months and extend survival. Participants receive up to 10 cycles of the drug combo, followed by ongoing maintenance therapy, and are monitored for up to 3 years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Weill Cornell Medicine
New York, New York, 10022, United States
Conditions
Explore the condition pages connected to this study.